Current and emerging treatment options i
β
Elias Jabbour; Jorge E. Cortes; Francis J. Giles; Susan O'Brien; Hagop M. Kantar
π
Article
π
2007
π
John Wiley and Sons
π
English
β 210 KB
## Abstract Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative BcrβAbl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases o